• (April 2015) FDA approves an expanded indication for Botox® (onabotulinumtoxinA) for the treatment of adults with upper limb spasticity, adding two thumb muscles: flexor pollicis longus and adductor pollicis.
  • (June 2015) FDA approves an in vitro assay for establishing the potency and stability of Xeomin® (incobotulinumtoxinA)
  • (July 2015) FDA approves Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity in adult patients to decrease the severity of increased muscle tone in elbow flexors, wrist flexors, and finger flexors.